



## ASX Release

### Prescient Therapeutics Presents at the 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference in New York

**Melbourne, Australia – (13 September 2016)** – Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) today announced it will be featured as a presenting company at the 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.

Mr Steven Yatomi-Clarke, of PTX will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link ([www.rodmanevents.com](http://www.rodmanevents.com)) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference  
Date: September 13, 2016  
Time: 9:10am (NY Time),  
Location: Louis Room; Lotte New York Palace Hotel in New York City

The presentation will be webcast live. To access the webcast, please visit [www.rodmanevents.com](http://www.rodmanevents.com). The webcast replay will remain available for 90 days following the live presentation.

**ENDS**

#### **About Prescient Therapeutics Limited (PTX)**

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.



PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

**Further enquiries:**

Steven Yatomi-Clarke  
CEO & Managing Director  
Prescient Therapeutics Limited  
+61 417 601 440